KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Equity Average: 2012-2025

Historic Equity Average for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $1.1 billion.

  • Supernus Pharmaceuticals' Equity Average rose 7.58% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 7.58%. This contributed to the annual value of $978.6 million for FY2024, which is 8.27% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Equity Average is $1.1 billion, which was up 0.91% from $1.0 billion recorded in Q2 2025.
  • Supernus Pharmaceuticals' Equity Average's 5-year high stood at $1.1 billion during Q3 2025, with a 5-year trough of $749.7 million in Q1 2021.
  • For the 3-year period, Supernus Pharmaceuticals' Equity Average averaged around $968.9 million, with its median value being $943.3 million (2024).
  • Data for Supernus Pharmaceuticals' Equity Average shows a peak YoY climbed of 24.03% (in 2021) over the last 5 years.
  • Supernus Pharmaceuticals' Equity Average (Quarterly) stood at $813.2 million in 2021, then increased by 6.93% to $869.5 million in 2022, then increased by 5.45% to $916.9 million in 2023, then rose by 11.41% to $1.0 billion in 2024, then grew by 7.58% to $1.1 billion in 2025.
  • Its Equity Average was $1.1 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.0 billion in Q1 2025.